For example, TAK‐242 (Resatorvid) was discovered to block the interaction between TLR4 and the adaptor proteins, the Toll‐interleukin‐1 receptor (TIR) domain containing adaptor protein (TIRAP) and TRIF‐related adaptor molecule (TRAM), to seize the signal transduction.[33] However, it failed the clinical trials in patients with severe sepsis, although the drug was well‐tolerated.[34] MicroRNAs were identified to efficiently regulate TLR signaling pathways,[35] but precisely delivering them to the target cells was still a big challenge for their clinical uses. Here, TIRAP is linked to Sepsis.